Skip to main content

Table 1 Baseline characteristics of the studied population

From: The role of matrix metalloproteinases in patients with pulmonary hypertension: data from a prospective study

   

Global

PH

Control

p

80

68

12

Age

Mean ± SD

 

72.56 ± 8.1471

73.01 ± 8.56

70.00 ± 4.59

p = 0.0847

Gender

Nr (%)

Male

25 (31.2%)

20 (29.41)

5 (41.66)

p = 0.6124

  

Female

55 (68.7%)

48 (70.58)

7 (58.33)

 

Body mass index

Mean ± SD

 

29.81 ± 6.21

29.65 ± 6.2807

30.70 ± 5.98

p = 0.5942

WHO

Nr (%)

I

5 (6.2%)

0 (0)

5 (41.66)

p < 0.0001

  

II [PHLHD(12), CTEPH(1), PHCOPD(1)]

21 (26.2%)

14 (20.58)

7 (58.33)

 
  

III [PHLHD(27), CTEPH(4), PHCOPD(6)]

37 (46.2%)

37 (54.41)

0 (0)

 
  

IV [PHLHD(9), CTEPH(5), PHCOPD(3)

17 (21.2%)

17 (25)

0 (0)

 

TIMP-4(pg/ml)

Mean ± SD

 

2723.88 ± 1352.40

2846.62 ± 1399.70

2028.38 ± 762.67

p = 0.0068

MMP-2(ng/ml)

Mean ± SD

 

96.12 ± 14.49

96.76 ± 14.10

92.47 ± 16.76

p = 0.3479

NT-proBNP *(pg/ml)

Median (mean ± SD)

 

2217.50 (4673.21 ± 6430.68)

2405.00 (5423.47 ± 6703.38)

411.0000 (421.75 ± 315.37)

p < 0.0001

Total cholesterol (mg/dl)

Mean ± SD

 

159.26 ± 48.99

155.03 ± 48.66

182.91 ± 45.75

p = 0.0691

Triglycerides * (mg/dl)

Median (mean ± SD)

 

103.50 (115.35 ± 54.36)

103.00 (109.39 ± 46.84)

116.00 (149.08 ± 79.95)

p = 0.0659

RA size (cm2)

Mean ± SD

 

25.86 ± 10.70

26.91 ± 11.15

19.90 ± 4.51

p = 0.0006

LA size (cm2) *

Median (mean ± SD)

 

30.70 (35.92 ± 29.37)

31.50 (38.06 ± 31.42)

24.10 (24.15 ± 5.36)

p = 0.0007

RD base diameter (cm)

Mean ± SD

 

48.36 ± 7.89

49.31 ± 7.58

43.00 ± 7.75

p = 0.0097

TAPSE (mm)

Mean ± SD

 

20.93 ± 4.44

20.39 ± 4.36

24.00 ± 3.71

p = 0.0088

sPAP (mmHg)

Mean ± SD

 

57.50 ± 21.48

62.90 ± 18.19

26.94 ± 10.01

p < 0.0001

  1. *Does not respect the normal distribution
  2. TIMP-4: Tissue inhibitor of matrix metalloproteinase’s; MMP-2: matrix metalloproteinase; NT-proBNP: N-terminal B-type natriuretic peptide; PHLHD: pulmonary hypertension due to left heart disease; CTEPH: chronic thromboembolic pulmonary hypertension; PHCOPD: pulmonary hypertension due to lung diseases and/or hypoxia; RA: right atrium; LA: left atrium; RD: right ventricle; TAPSE: tricuspid annular plane systolic excursion; sPAP: systolic pulmonary arterial pressure